Flagstar Bancorp Inc (FBC)

[oldberkeley]

I know the stock that you're talking about, CRBC, and yes, it did quite well after the RS.

While statistically reverse splits fail more often than not, the fundamental health of the company is usually the deciding factor. With many small biotechs, it's just a way of postponing the inevitable: a reverse split does not make the drug any better.

However, with banks--and I'm hoping with FBC in particular--it will serve not only the primary purpose of meeting the NYSE listing regulation but also stimulate institutional buying.

Best of luck.